The FDA has approved the drug to treat rheumatoid arthritis, Actemra, the only product on the market that will actively prevent this inflammatory process at the source. Although there are 9 biologically designed products on the market that will treat certain forms of arthritis, Actemra is the only drug that is targeting the disease at the molecular level.

Actemra prevent the arthritis by effectively halting the processing ability of a specific molecular protein known as Interleukin 6 which is known to cause inflammation in the bones and joints of the human body.